Status:
RECRUITING
Signature of the Host Response to a Respiratory Viral Infection, in the Prediction of Bronchiolitis Obliterans
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Allogeneic Hematopoietic Stem Cell Recipients
Acute Respiratory Infection
Eligibility:
All Genders
18+ years
Brief Summary
Bronchiolitis obliterans (BO) is the well-known manifestation of the chronic pulmonary graft-versus-host disease(GVHD) after allogeneic hematopoietic stem cell transplantation (HSCT). The pathophysiol...
Eligibility Criteria
Inclusion
- Inclusion Criteria :
- Adults having received a hematopoietic stem cell transplantation for less than two years
- Availability of respiratory function tests prior to infection
- Presence of PIV respiratory infection documented by identification of the virus by PCR in the upper and/or lower respiratory tract
- Symptoms of respiratory infection ≤ 5 days
- Signed informed consent
- Exclusion Criteria:
- Presence of a respiratory virus infection other than PIV
- Viral respiratory co-infections
- Bacterial or fungal respiratory infections
- Treatment with ribavirin, oseltamivir or any other antiviral with activity against respiratory viruses
- Patient not affiliated or beneficiary of a social security system
- Patient deprived of liberty or protected
- Pregnant or breastfeeding woman
Exclusion
Key Trial Info
Start Date :
March 1 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
March 1 2025
Estimated Enrollment :
14 Patients enrolled
Trial Details
Trial ID
NCT04099082
Start Date
March 1 2021
End Date
March 1 2025
Last Update
July 17 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Saint Louis
Paris, Île-de-France Region, France, 75010